Seven Firms Advise on Mylan's $1.6 Billion Generic Drug Buy

Global generic drug and specialty pharmaceuticals maker Mylan has turned to Skadden, Arps, Slate, Meagher & Flom, Magic Circle shop Slaughter and May, and Indian firm Platinum Partners for counsel on its $1.6 billion acquisition of Indian generic injectable drug manufacturer Agila Specialties from parent Strides Arcolab. Haynes and Boone, Herbert Smith Freehills, and firms from Brazil and India are advising the seller.

This article requires premium access

This article requires premium access to The American Lawyer. Please sign in or subscribe to read the full text.